NasdaqGM:IRONBiotechs
Disc Medicine (IRON) Valuation Check as FDA Scrutiny and Bitopertin Trial Milestones Drive Volatility
Disc Medicine (IRON) is suddenly in the spotlight as questions from FDA officials, media scrutiny, and insider selling collide with management’s upbeat tone on bitopertin and its National Priority Voucher pathway.
See our latest analysis for Disc Medicine.
That tension is showing up in the tape: despite a 1 day share price return of minus 11.5 percent and a 7 day and 30 day share price pullback, the 90 day and year to date share price returns remain strongly positive. The 1 year total...